目的 探討檢測超敏C反應蛋白（hs-CRP）、白細胞介素6（IL-6）、降鈣素原（PCT）對新型冠狀病毒肺炎（COVID-19）患者預后評估的臨床價值。方法 選擇150例COVID-19患者按診斷標準分為4組：輕型組（48例）、普通型組（45例）、重型組（35例）、危重型組（22例），測定各組患者血清hs-CRP、IL-6、PCT水平，并分析血清hs-CRP、IL-6、PCT水平對COVID-19患者預后評估以及對死亡風險的預測。結果 對于血清hs-CRP、IL-6、PCT水平，危重型組 > 重型組 > 普通型組 > 輕型組，差異均有統(tǒng)計學意義（P<0.05）。隨著患者病情的加重，APACHE II評分也逐漸升高，但差異無統(tǒng)計學意義。血清hs-CRP、IL-6、PCT三者聯合檢測對患者預后的判斷強于單一項目。與存活組比較，死亡組的hs-CRP、IL-6、PCT明顯升高，兩組比較差異具有統(tǒng)計學意義（P<0.05）。血清hs-CRP、IL-6、PCT水平聯合檢測在預測COVID-19死亡風險的準確率大于單一項目（P<0.05），與APACHE II評分相差不大。結論 血清hs-CRP、IL-6、PCT聯合檢測有助于判斷COVID-19患者的預后，并且可以用來評估COVID-19患者的死亡風險。

Objective To explore the clinical value of detecting hs-CRP, interleukin 6(IL-6) and procalcitonin (PCT) in evaluating the prognosis of patients with COVID-19. Methods Patients (150 cases) with COVID-19 were divided into four groups according to diagnostic criteria:mild group (48 cases), normal group (45 cases), serious group (35 cases), and critical group (22 cases). The serum levels of hs-CRP, IL-6, and PCT were measured, serum levels of hs-CRP, IL-6, and PCT were analyzed to assess the prognosis of COVID-19 and to predict the risk of death. Results For the levels of hs-CRP, IL-6, and PCT, the critical group > serious group > normal group > mild group, with significant difference (P<0.05). APACHE II score increased with the progression of COVID-19, but there was no significant difference. The combined detection of hs-CRP, IL-6, and PCT was more effective than the single item in predicting the prognosis of patients. Compared with the survival group, hs-CRP, IL-6, and PCT in death group were significantly increased (P<0.05). The accuracy in predicting the risk of death from COVID-19 of the combined detection of hs-CRP, IL-6, and PCT was more than the detection of single item (P<0.05), and similar to that of APACHE II. Conclusion The combination of serum hs-CRP, IL-6, and PCT can be used to predict the prognosis of patients with COVID-19 and to assess the risk of death in patients with COVID-19.

R927.1